SERPINA1 and alpha 1-antitrypsin deficiency: One success can be observed in the orphan drug designation Organovo received in 2017 from the FDA for their 3D bioprinted liver tissues used in the treatment of alpha-1 antitrypsin (A1AT) deficiency [264].